rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Teri L. Lawver

SVP & Chief Commercial Officer

Company insider

Files Form 4 as: SVP & Chief Commercial Officer, Celldex Therapeutics; Director, Altimmune; EVP Chief Commercial Officer, DexCom.

In numbers

Trades disclosed
10
Buys
0
Sells
1
Bought
$0
Sold
$640K
Companies
3
Companies where not an officer
1
First trade
8 Mar 2023
Last trade
25 Jun 2026
Last filed
29 Jun 2026

Companies traded

Where they are an officer
CLDX Celldex TherapeuticsOfficer · Diagnostics & Labs · last 25 Jun 20260 buys · 0 sells
DXCM DexComOfficer · Medical Devices · last 12 Mar 20240 buys · 1 sell
Everywhere else they filed: board seats, 10% stakes, other companies
ALT AltimmuneDirector · Biotechnology · last 1 May 20260 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
101Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
25 Jun 2026filed 29 Jun 2026CLDX Celldex Therapeuticsoption or derivative · Diagnostics & LabsSEC FORM 4 Code A—90,000 at $0.00filing
25 Jun 2026filed 29 Jun 2026CLDX Celldex Therapeuticsoption or derivative · Diagnostics & LabsSEC FORM 4 Code A—90,000 at $0.00filing
1 May 2026filed 1 May 2026ALT Altimmuneoption or derivative · BiotechnologySEC FORM 4 Code A—48,800 at $0.00filing
1 May 2026filed 1 May 2026ALT Altimmuneoption or derivative · BiotechnologySEC FORM 4 Code A—48,800 at $0.00filing
10 Nov 2025filed 12 Nov 2025CLDX Celldex Therapeuticsoption or derivative · Diagnostics & LabsSEC FORM 4 Code A—100,000 at $0.00filing
25 Sep 2025filed 29 Sep 2025ALT Altimmuneoption or derivative · BiotechnologySEC FORM 4 Code A—48,800 at $0.00filing
24 Feb 2025filed 26 Feb 2025ALT Altimmuneoption or derivative · BiotechnologySEC FORM 4 Code A—69,800 at $0.00filing
12 Mar 2024filed 14 Mar 2024DXCM DexComMedical DevicesSEC FORM 4 Sold$640K4,764 at $134.41filing
8 Mar 2024filed 11 Mar 2024DXCM DexComMedical DevicesSEC FORM 4 Code A—26,053 at $0.00filing
8 Mar 2023filed 10 Mar 2023DXCM DexComMedical DevicesSEC FORM 4 Code A—45,352 at $0.00filing

News

Vontobel Holding Ltd. Sells 14,970 Shares of DexCom, Inc. $DXCMDXCM · dailypolitical.com · 20 Oct 2026DexCom, Inc. $DXCM Position Lowered by Gradient Investments LLCDXCM · dailypolitical.com · 8 Oct 2026

0 headlines in the last 90 days name Teri L. Lawver; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.

Sectors

Health Care1

Buys in green, sells in red, by the company’s sector.

Related people

Michael Jon BrownEVP Chief Legal Compliance Off · EVP Chief Legal Compliance Off at Dexcom, filing Form 4 there in the last year
Sadie SternEVP Chief People & Culture Off · EVP Chief People & Culture Off at Dexcom, filing Form 4 there in the last year
Nicholas AugustinosDirector · Director at Dexcom, filing Form 4 there in the last year
Jereme M. SylvainEVP, Chief Financal Officer · EVP, Chief Financal Officer at Dexcom, filing Form 4 there in the last year
Glenn S. BoehnleinDirector · Director at Dexcom, filing Form 4 there in the last year
Kevin R. SayerExecutive Chair · Also traded DXCM in the last 90 days
Bridgette P. HellerDirector · Also traded DXCM in the last 90 days
Mark G. FolettaDirector · Also traded DXCM in the last 90 days